SR2162

SR2162 is an investigational small molecule therapeutic being developed by Shanghai SimrBio Bioscience (SimrBio) for the treatment of chronic pain. As of early 2024, the candidate is in the IND-enabling stage of development. SimrBio's research platform is dedicated to the discovery of non-opioid analgesics that target peripheral nervous system mechanisms, aiming to provide effective pain relief without the central nervous system side effects or addiction potential associated with traditional therapies. While the specific biological target of SR2162 has not been publicly disclosed, it is part of a broader pipeline focused on ion channels and receptors involved in pain signaling.